Cargando…

Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body

BACKGROUND: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under discussion for its pathogenicity because there is no clinical report showing pathological e...

Descripción completa

Detalles Bibliográficos
Autores principales: Oikawa, Masayoshi, Sakamoto, Nobuo, Kobayashi, Atsushi, Suzuki, Satoshi, Yoshihisa, Akiomi, Yamaki, Takayoshi, Nakazato, Kazuhiko, Suzuki, Hitoshi, Saitoh, Shu-ichi, Kiko, Yuichirou, Nakano, Hajime, Hayashi, Takeharu, Kimura, Akinori, Takeishi, Yasuchika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862085/
https://www.ncbi.nlm.nih.gov/pubmed/27160240
http://dx.doi.org/10.1186/s12872-016-0262-y
_version_ 1782431305704669184
author Oikawa, Masayoshi
Sakamoto, Nobuo
Kobayashi, Atsushi
Suzuki, Satoshi
Yoshihisa, Akiomi
Yamaki, Takayoshi
Nakazato, Kazuhiko
Suzuki, Hitoshi
Saitoh, Shu-ichi
Kiko, Yuichirou
Nakano, Hajime
Hayashi, Takeharu
Kimura, Akinori
Takeishi, Yasuchika
author_facet Oikawa, Masayoshi
Sakamoto, Nobuo
Kobayashi, Atsushi
Suzuki, Satoshi
Yoshihisa, Akiomi
Yamaki, Takayoshi
Nakazato, Kazuhiko
Suzuki, Hitoshi
Saitoh, Shu-ichi
Kiko, Yuichirou
Nakano, Hajime
Hayashi, Takeharu
Kimura, Akinori
Takeishi, Yasuchika
author_sort Oikawa, Masayoshi
collection PubMed
description BACKGROUND: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under discussion for its pathogenicity because there is no clinical report showing pathological evidence of Fabry disease with E66Q mutation. CASE PRESENTATION: A 65-year-old Japanese female was referred to our hospital for chest discomfort on effort. Transthoracic echocardiography showed severe left ventricular (LV) hypertrophy with LV outflow obstruction. Maximum LV outflow pressure gradient was 87 mmHg, and Valsalva maneuver increased the pressure gradient up to 98 mmHg. According to medical interview, one of her younger sister and a nephew died suddenly at age 42 and 36, respectively. Another younger sister also presented LV hypertrophy with outflow obstruction. Maximum LV outflow pressure gradient was 100 mmHg, and the E66Q mutation was detected similar to the case. Endomyocardial biopsy specimens presented vacuolation of cardiomyocytes, in which zebra bodies were detected by electron microscopic examination. Although the enzymatic activity of GLA was within normal range, the c. 196G>C nucleotide change, which lead to the E66Q mutation of GLA gene, was detected. We initially diagnosed her as cardiac Fabry disease based on the findings of zebra body. However, immunostaining showed few deposition of globotriaosylceramide in left ventricular myocardium, and gene mutations in the disease genes for hypertrophic cardiomyopathy (HCM), MYBPC3 and MYH6, were detected. Although the pathogenicity of the E66Q mutation cannot be ruled out, hypertrophic obstructive cardiomyopathy (HOCM) was more reasonable to explain the pathophysiology in the case. CONCLUSIONS: This is the confusable case of HOCM with Fabry disease with the GLA E66Q mutation. We have to take into consideration the possibility that some patients with the E66Q mutation may have similar histological findings of Fabry disease, and should be examed the possibility for harboring gene mutations associated with HCM.
format Online
Article
Text
id pubmed-4862085
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48620852016-05-11 Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body Oikawa, Masayoshi Sakamoto, Nobuo Kobayashi, Atsushi Suzuki, Satoshi Yoshihisa, Akiomi Yamaki, Takayoshi Nakazato, Kazuhiko Suzuki, Hitoshi Saitoh, Shu-ichi Kiko, Yuichirou Nakano, Hajime Hayashi, Takeharu Kimura, Akinori Takeishi, Yasuchika BMC Cardiovasc Disord Case Report BACKGROUND: Fabry disease is caused by mutations in the α-galactosidase A (GLA) gene, which is located in X-chromosome coding for the lysosomal enzyme of GLA. Among many gene mutations, E66Q mutation is under discussion for its pathogenicity because there is no clinical report showing pathological evidence of Fabry disease with E66Q mutation. CASE PRESENTATION: A 65-year-old Japanese female was referred to our hospital for chest discomfort on effort. Transthoracic echocardiography showed severe left ventricular (LV) hypertrophy with LV outflow obstruction. Maximum LV outflow pressure gradient was 87 mmHg, and Valsalva maneuver increased the pressure gradient up to 98 mmHg. According to medical interview, one of her younger sister and a nephew died suddenly at age 42 and 36, respectively. Another younger sister also presented LV hypertrophy with outflow obstruction. Maximum LV outflow pressure gradient was 100 mmHg, and the E66Q mutation was detected similar to the case. Endomyocardial biopsy specimens presented vacuolation of cardiomyocytes, in which zebra bodies were detected by electron microscopic examination. Although the enzymatic activity of GLA was within normal range, the c. 196G>C nucleotide change, which lead to the E66Q mutation of GLA gene, was detected. We initially diagnosed her as cardiac Fabry disease based on the findings of zebra body. However, immunostaining showed few deposition of globotriaosylceramide in left ventricular myocardium, and gene mutations in the disease genes for hypertrophic cardiomyopathy (HCM), MYBPC3 and MYH6, were detected. Although the pathogenicity of the E66Q mutation cannot be ruled out, hypertrophic obstructive cardiomyopathy (HOCM) was more reasonable to explain the pathophysiology in the case. CONCLUSIONS: This is the confusable case of HOCM with Fabry disease with the GLA E66Q mutation. We have to take into consideration the possibility that some patients with the E66Q mutation may have similar histological findings of Fabry disease, and should be examed the possibility for harboring gene mutations associated with HCM. BioMed Central 2016-05-10 /pmc/articles/PMC4862085/ /pubmed/27160240 http://dx.doi.org/10.1186/s12872-016-0262-y Text en © Oikawa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Oikawa, Masayoshi
Sakamoto, Nobuo
Kobayashi, Atsushi
Suzuki, Satoshi
Yoshihisa, Akiomi
Yamaki, Takayoshi
Nakazato, Kazuhiko
Suzuki, Hitoshi
Saitoh, Shu-ichi
Kiko, Yuichirou
Nakano, Hajime
Hayashi, Takeharu
Kimura, Akinori
Takeishi, Yasuchika
Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
title Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
title_full Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
title_fullStr Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
title_full_unstemmed Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
title_short Familial hypertrophic obstructive cardiomyopathy with the GLA E66Q mutation and zebra body
title_sort familial hypertrophic obstructive cardiomyopathy with the gla e66q mutation and zebra body
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862085/
https://www.ncbi.nlm.nih.gov/pubmed/27160240
http://dx.doi.org/10.1186/s12872-016-0262-y
work_keys_str_mv AT oikawamasayoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT sakamotonobuo familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT kobayashiatsushi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT suzukisatoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT yoshihisaakiomi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT yamakitakayoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT nakazatokazuhiko familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT suzukihitoshi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT saitohshuichi familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT kikoyuichirou familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT nakanohajime familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT hayashitakeharu familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT kimuraakinori familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody
AT takeishiyasuchika familialhypertrophicobstructivecardiomyopathywiththeglae66qmutationandzebrabody